Pre-clinical toxicology and pathology of 9-(2′-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs

Life Sciences

Volumn 79, Issue 14, 2006, Pages 1334-1342

  Ashok, B T ^a   Tadi, K ^a   Banerjee, D ^b   Konopa, J ^c   Iatropoulos, M ^a   Tiwari, R K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Chemotherapy; Maximum tolerated dose; Nitroacridine derivative; Prostate cancer; Toxicity

Indexed keywords

9 (2' HYDROXYETHYLAMINO) 4 METHYL 1 NITROACRIDINE; ACRIDINE DERIVATIVE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; C 1748; CREATINE KINASE; UNCLASSIFIED DRUG;

AGGRESSION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DISORIENTATION; DOG; DRUG MEGADOSE; DRUG SCREENING; EXTRAVASATION; HYPERTROPHY; INTESTINE MUCOSA; LEUKOCYTE COUNT; LYMPH NODE HYPERPLASIA; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PROSTATE CANCER; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VOMITING;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BILE DUCTS; BLOOD CELL COUNT; BODY WEIGHT; DOGS; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LEUKOPENIA; LIVER FUNCTION TESTS; LYMPH NODES; MALE; MYOCARDIUM; NITRACRINE; THROMBOCYTOPENIA; VOMITING; WATER-ELECTROLYTE BALANCE;

CANIS FAMILIARIS;

EID: 33747042452     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.03.043     Document Type: Article

References (41)

1. Armstrong A.J., and Carducci M.A. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Current Oncology Reports 7 3 (2005) 220-227
2. Bratkowska-Seniow B., Oleszkiewicz L., Kozak E., and Krizar T. Ledakrin in the treatment of colon carcinoma. Materia Medica Polona (English Ed.) 8 3 (1976) 323-330
3. Colombo P., Gunnarsson K., Iatropoulos M., and Brughera M. Toxicological testing of cytotoxic drugs (Review). International Journal of Oncology 19 5 (2001) 1021-1028
4. Denny W.A. Acridine derivatives as chemotherapeutic agents. Current Medicinal Chemistry 9 18 (2002) 1655-1665
5. Doroshow J.H., Tallent C., and Schechter J.E. Ultrastructural features of adriamycin induced skeletal and cardiac muscle toxicity. American Journal of Pathology 118 2 (1985) 288-297
6. Eichenberger T., and Trachtenberg J. Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer. Canadian Journal of Surgery 32 5 (1989) 349-352
7. Gniazdowski M., and Szmigiero L. Nitracrine and its congeners-an overview. General Pharmacology 26 3 (1995) 473-481
8. Goodin D.E. Therapy-related leukemia in mitoxantrone treated patients. Multiple Sclerosis 9 4 (2003) 426
9. Goodin S., Rao K.V., and DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7 4 (2002) 360-370
10. Goodin S., Medina P., Capanna T., Shih W.J., Abraham S., Winnie J., Doyle-Lindrud S., Todd M., and DiPaola R.S. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. Journal of Clinical Oncology 23 15 (2005) 3352-3357
11. Gorlewska K., Mazerska Z., Sowinski P., and Konopa J. Products of metabolic activation of the antitumor drug ledakrin (Nitracrine) in vitro. Chemical Research in Toxicology 14 1 (2001) 1-10
12. Gulley J., and Dahut W.L. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. Urology 62 Suppl. 1 (2003) 147-154
13. Iatropoulos M.J. Anthracyclin cardiomyopathy: predictive value of animal models. Cancer Treatment Symposia 3 (1984) 3-17
14. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., Trump D., Winer E.P., and Vogelzang N.J. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of Clinical Oncology 17 8 (1999) 2506-2513
15. Keyomarsi K., and Pardee A.B. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Progress in Cell Cycle Research 5 (2003) 527-532
16. Konopa J., Pawlak J.W., and Pawlak K. The mode of action of cytotoxic and antitumor 1-nitroacridines. III. In vivo interstrand cross-linking of DNA of mammalian or bacterial cells by 1-nitroacridines. Chemistry and Biology Interactions 43 2 (1983) 175-197
17. Konopa, J., Wysocka-Skrzela, B., Tiwari, R.K., 2003. 9-alkylamino-1-1nitroacridine derivatives. Patent. US6589, 961B2.
18. La Porta C.A. Cellular targets for anticancer strategies. Current Drug Targets 5 4 (2004) 347-355
19. 2O. Materia Medica Polona 8 3 (1976) 237-251
20. Lee H.H., Wilson W.R., and Denny W.A. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide onhypoxia-selective cytotoxicity. Anticancer Drug Discovery 14 6 (1999) 487-497
21. Marchini S., D'Incalci M., and Broggini M. New molecules and strategies in the field of anticancer agents. Current Medicinal Chemistry Anticancer Agents 4 3 (2004) 247-262
22. Mazerska Z., Lukowicz J., and Konopa J. Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors. Arzneimittelforschung 40 4 (1990) 472-477
23. Morris M.J., Santamauro J., Shia J., Schwartz L., Vander Els N., Kelly K., and Scher H. Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology 60 6 (2002) 1111
24. Narayanan R., Tiwari P., Inoa D., and Ashok B.T. Comparative analysis of mutagenic potency of 1-nitro-acridine derivatives. Life Science 77 18 (2005) 2312-2323
25. Oh W.K., Hagmann E., Manola J., George D.J., Gilligan T.D., Jacobson J.O., Smith M.R., Kaufman D.S., and Kantoff P.W. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clinical Cancer Research 11 1 (2005) 284-289
26. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB Journal 4 13 (1990) 3076-3086
27. Papandreou C.N., Daliani D.D., Thall P.F., Tu S.M., Wang X., Reyes A., Troncoso P., and Logothetis C.J. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. Journal of Clinical Oncology 20 14 (2002) 3072-3080
28. Pawlak J.W., and Konopa J. In vitro binding of metabolically activated [14C]-ledakrin, or 1-nitro-9-14C-(3′-dimethyl-amino-N-propylamino)acridine, a new antitumor and DNA crosslinking agent, to macromolecules of subcellular fractions isolated from rat liver and HeLa cells. Biochemical Pharmacology 28 (1979) 3391-3402
29. Pawlak J.W., Pawlak K., and Konopa J. The mode of action of cytotoxic and antitumor 1-nitroacridines. II. In vivo enzyme-mediated covalent binding of a 1-nitroacridine derivative, ledakrin or nitracrine, with DNA and other macromolecules of mammalian or bacterial cells. Chemistry and Biology Interactions 43 2 (1983) 151-173
30. Pawlak K., Pawlak J.W., and Konopa J. Cytotoxic and antitumor activity of 1-nitroacridines as an after effect of their interstrand DNA cross-linking. Cancer Research 44 10 (1984) 4289-4296
31. Petrylak D.P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65 Suppl. 5 (2005) 3-7
32. Picus J., and Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Seminars in Oncology 26 5 Suppl. 17 (1999) 14-18
33. Savarese D.M., Halabi S., Hars V., Akerley W.L., Taplin M.E., Godley P.A., Hussain A., Small E.J., and Vogelzang N.J. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Journal of Clinical Oncology 19 9 (2001) 2509-2516
34. Skladanowski A. Modulation of G (2) arrest enhances cell death induced by the antitumor 1-nitroacridine derivative, nitracrine. Apoptosis 7 4 (2002) 347-359
35. Small E.J., Baron A., and Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80 9 (1997) 1755-1759
36. Tadi K., Chen Y.G., Ashok B.T., Garikapaty V.P.S., Banerjee D., Wysocka-Skrzela B., Konopa J., and Tiwari R.K. Capridine ß (C-1748): a novel 1-nitroacridine derivative targets the cyclin dependent kinase, cdk4 and the tumor suppressor gene, p16 in prostate cancer. Proceedings of the American Association for Cancer Research 45 (2004) (Abstract # 3036)
37. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M., and Murphy K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology 14 6 (1996) 1756-1764
38. Vaishampayan U., Fontana J., Du W., and Hussain M. An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology 60 6 (2002) 1050-1054
39. van Dalen E.C., Van der Pal H.J., Bakker P.J., Caron H.N., and Kremer L.C. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. European Journal of Cancer 40 5 (2004) 643-652
40. Wagstaff A.J., Ward A., Benfield P., and Heel R.C. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37 2 (1989) 162-190
41. Wilson W.R., Denny W.A., Twigden S.J., Baguley B.C., and Probert J.C. Selective toxicity of nitracrine to hypoxic mammalian cells. British Journal of Cancer 49 2 (1984) 215-223